Document is current
Any future updates will be listed below
-
Authors
Goossens, Julie http://orcid.org/0000-0001-5336-1238
Cervantes González, Alba http://orcid.org/0000-0003-1006-6719
Dewit, Nele http://orcid.org/0000-0002-4062-8711
Lidón, Laia http://orcid.org/0000-0002-2083-3515
Fortea, Juan http://orcid.org/0000-0002-1340-638X
Alcolea, Daniel http://orcid.org/0000-0002-3819-3245
Lleó, Alberto http://orcid.org/0000-0002-2568-5478
Belbin, Olivia http://orcid.org/0000-0002-6109-6371
Vanmechelen, Eugeen http://orcid.org/0000-0002-9466-5366
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00327, PI21/00327, DTS-22/00111, PI18/00435 and INT19/00016, PI18/00327, PI21/00327, DTS-22/00111, PI18/00435 and INT19/00016)
Network of Centres of Excellence in Neurodegeneration (COEN5025)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (Program 1)
Fondo Europeo de Desarrollo Regional ("Una manera de hacer Europa")
Department of Health Generalitat de Catalunya (AGAUR 2019 PROD 00088)
- License Information
-
More Information
Article History
Received: 31 May 2023
Accepted: 17 October 2023
First Online: 28 October 2023
Declarations
:
: This study was reviewed and approved by the IRB and was conducted in accordance with the Declaration of Helsinki. All participants gave their written informed consent to participate in the study. All animal experiments were performed in accordance with the ARRIVE guidelines, following good laboratory practices and ethical regulations.
: Not applicable.
: E.V. is co-founder of ADx NeuroSciences NV, Zwijnaarde (Ghent), Belgium, J.G. is employee at ADx NeuroSciences NV, N. D. was an employee at ADx NeuroSciences at the time of this research work and is now employee at Medpace Laboratories. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Lilly and Esteve Pharmaceuticals. D. A, J.F., A.L. and O.B. declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) related to biomarkers included in this manuscript.
